Product Information

VERAPAMIL ER 180 MG TABLET is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $0.2056 per EA under NDC 75834015801. Its NADAC has been published 384 times since Jul 17, 2019.

FDA first approved this application on May 5, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

VERAPAMIL ER 180 MG TABLET

VERAPAMIL HYDROCHLORIDE
$0.2056per EA

Strength

180 mg/1

NDC

75834015801

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

VERAPAMIL HYDROCHLORIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA206173

FDA Approved

5/5/2017

TE Code

AB

On Market Since

5/15/2019

Pharmacological Classes

Calcium Channel Antagonists
Calcium Channel Blocker
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A4 Inhibitors
P-Glycoprotein Inhibitors

Price Statistics

The NADAC for VERAPAMIL ER 180 MG TABLET has been published 384 times since Jul 17, 2019, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$0.2056 per EA
All-time high$0.2281 (Apr 15, 2020)
All-time low$0.1572 (Nov 20, 2024)
52-week high$0.2056
52-week low$0.1836
Median price$0.1930
Average price$0.1948
Largest weekly change-17.6% (Nov 20, 2024)
Weeks tracked384
Tracking sinceJul 17, 2019

Price History

1W

+5.8%

1M

+7.6%

3M

+7.6%

6M

+6.4%

1Y

+15.0%

3Y

+9.0%

5Y

-1.7%

All

+1.9%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 7% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 7%

1 alternative • Same active ingredient

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of VERAPAMIL ER 180 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for VERAPAMIL ER 180 MG TABLET, manufactured by Nivagen Pharmaceuticals Inc., is $0.2056 per EA (NDC 75834015801), effective Nov 18, 2026.

How has the price of VERAPAMIL ER 180 MG TABLET changed over time?

Over the history we have for it, the NADAC for VERAPAMIL ER 180 MG TABLET has held within roughly two percent of its current level. It has been tracked across 384 weekly CMS publications since Jul 17, 2019.

What are the highest and lowest recorded NADAC prices for VERAPAMIL ER 180 MG TABLET?

Since Jul 17, 2019, the NADAC for VERAPAMIL ER 180 MG TABLET has ranged from a low of $0.1572 (Nov 20, 2024) to a high of $0.2281 (Apr 15, 2020), with a median of $0.1930 per EA.

Are there cheaper alternatives to VERAPAMIL ER 180 MG TABLET?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VERAPAMIL ER 180 MG TABLET, is $0.1914 per EA — about 7% below VERAPAMIL ER 180 MG TABLET.

Who manufactures VERAPAMIL ER 180 MG TABLET?

VERAPAMIL ER 180 MG TABLET (NDC 75834015801) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.